Extended report: Ofatumumab a fully human anti-CD20 monoclonal antibody in biological-naive rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised double-blind placebo-controlled clinical trial

摘要

ObjectivesTo evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment.